Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14051 - 14075 of 14985 in total
Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational
Matched Description: … Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus. …
Experimental
Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
Investigational
Matched Description: … Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin …
Experimental
Experimental
PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors.
Investigational
Matched Description: … PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors. …
Experimental
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … Different Formulations Of PF-04937319 In Healthy Subjects). ... 04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … A Modified Release Formulation of PF-06650833 in Healthy Subjects). ... PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of
Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Investigational
Matched Description: … Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer). …
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
Matched Description: … It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. ... Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer …
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Description: … Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects). ... PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple …
Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational
Matched Description: … Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee). ... Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 …
HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).
Investigational
Matched Description: … of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation). ... HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients …
TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.
Investigational
Matched Description: … TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic …
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Matched Description: … It is a member of a new family of pharmaceutical compounds called vomeropherins. ... PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized …
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
Displaying drugs 14051 - 14075 of 14985 in total